Exact Mass: 433.1557
Exact Mass Matches: 433.1557
Found 157 metabolites which its exact mass value is equals to given mass value 433.1557
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
(2R)-1-[4-[1,3-Benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
2-Methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents
4-Nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
1-(2-Methyl-4-methoxyphenyl)-4-((2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline
D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors
N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide
Nitrile,1-O-beta-rutinoside-glucopyranoside,penta-Ac-1,4-Dihydroxy-2-cyclopentene-1-carboxylic acid
12-[(2,4-dimethoxyphenyl)carbonyl]-6a,6b,10,11,11a,12-hexahydro-8,11-epoxyoxepino[4,5:3,4]pyrrolo[1,2-a]quinolin-7(8H)-one
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.276 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.275 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.279
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based on: CCMSLIB00000846974]
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based: Match]
Cys Asn Pro Thr
Cys Asn Thr Pro
Cys Pro Asn Thr
Cys Pro Gln Ser
Cys Pro Ser Gln
Cys Pro Thr Asn
Cys Gln Pro Ser
Cys Gln Ser Pro
Cys Ser Pro Gln
Cys Ser Gln Pro
Cys Thr Asn Pro
Cys Thr Pro Asn
Asp Gly Gly Trp
Asp Gly Trp Gly
Asp Trp Gly Gly
Gly Asp Gly Trp
Gly Asp Trp Gly
Gly Gly Asp Trp
Gly Gly Trp Asp
Gly Trp Asp Gly
Gly Trp Gly Asp
Asn Cys Pro Thr
Asn Cys Thr Pro
Asn Pro Cys Thr
Asn Pro Thr Cys
Asn Thr Cys Pro
Asn Thr Pro Cys
Pro Cys Asn Thr
Pro Cys Gln Ser
Pro Cys Ser Gln
Pro Cys Thr Asn
Pro Asn Cys Thr
Pro Asn Thr Cys
Pro Gln Cys Ser
Pro Gln Ser Cys
Pro Ser Cys Gln
Pro Ser Gln Cys
Pro Thr Cys Asn
Pro Thr Asn Cys
Gln Cys Pro Ser
Gln Cys Ser Pro
Gln Pro Cys Ser
Gln Pro Ser Cys
Gln Ser Cys Pro
Gln Ser Pro Cys
Ser Cys Pro Gln
Ser Cys Gln Pro
Ser Pro Cys Gln
Ser Pro Gln Cys
Ser Gln Cys Pro
Ser Gln Pro Cys
Thr Cys Asn Pro
Thr Cys Pro Asn
Thr Asn Cys Pro
Thr Asn Pro Cys
Thr Pro Cys Asn
Thr Pro Asn Cys
Trp Asp Gly Gly
Trp Gly Asp Gly
Trp Gly Gly Asp
4-BROMO-N-DODECYL-1-HYDROXY-2-NAPHTHALENECARBOXAMIDE
Lubeluzole
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D002317 - Cardiovascular Agents D020011 - Protective Agents
(4-Nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively[1].
N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide
1-(4-(Benzo[d]thiazol-2-yl(methyl)amino)piperidin-1-yl)-3-(3,4-difluorophenoxy)propan-2-ol
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
N-{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl}-2-methylpropanamide
2-[[7-(4-Methoxyphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]thio]propanoic acid ethyl ester
1-(4-methylphenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea
N-(2,5-dimethoxyphenyl)sulfonyl-N-(4-methoxyphenyl)cyclohexanecarboxamide
4-[2-Benzofuranyl(oxo)methyl]-1-[2-(4-morpholinyl)ethyl]-5-(3-pyridinyl)pyrrolidine-2,3-dione
N-[(2R,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2R,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
2-[(2R,3S,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,3S,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3R,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
N-[(2R,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
(1R,2aS,8bS)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,2aR,8bR)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
[(2S,3R)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
[(2S,3S)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
N-[(2R,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
2-[(2S,3R,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3S,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
N-[(2S,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
(1S,2aR,8bR)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1S,2aS,8bS)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
[(2R,3R)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
5-(3,4-Dimethoxyphenyl)-4-(furan-2-carbonyl)-1-(2-phenylethyl)pyrrolidine-2,3-dione
PHT-7.3
PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity[1].